| Post-Transplantation Cyclophosphamide-Based Graft-versus-Host Disease Prophylaxis Bolaños-Meade J, H M, W J, BMTCTNIBCMPI Al Malki MM New England Journal of Medicine 388 (25), 2338-2348, 2023 | 150 | 2023 |
| New and emerging therapies for acute and chronic graft versus host disease LQ Hill, A Alousi, P Kebriaei, R Mehta, K Rezvani, E Shpall Therapeutic advances in hematology 9 (1), 21-46, 2018 | 144 | 2018 |
| Safety and anti-tumor activity of CD5 CAR T-cells in patients with relapsed/refractory T-cell malignancies LQC Hill, RH Rouce, TS Smith, L Yang, M Srinivasan, H Zhang, ... Blood 134, 199, 2019 | 67 | 2019 |
| Clinical effects of administering leukemia-specific donor T cells to patients with AML/MDS after allogeneic transplant PD Lulla, S Naik, S Vasileiou, I Tzannou, A Watanabe, M Kuvalekar, ... Blood, The Journal of the American Society of Hematology 137 (19), 2585-2597, 2021 | 46 | 2021 |
| Feasibility and preclinical efficacy of CD7-unedited CD7 CAR T cells for T cell malignancies N Watanabe, F Mo, R Zheng, R Ma, VC Bray, DG van Leeuwen, ... Molecular Therapy 31 (1), 24-34, 2023 | 36 | 2023 |
| The use of chimeric antigen receptor T cells in patients with non-Hodgkin lymphoma PD Lulla, LQC Hill, CA Ramos, HE Heslop Clinical advances in hematology & oncology: H&O 16 (5), 375, 2018 | 23 | 2018 |
| Long-term follow-up for the development of subsequent malignancies in patients treated with genetically modified IECs DHM Steffin, IN Muhsen, LQC Hill, CA Ramos, N Ahmed, M Hegde, ... Blood, The Journal of the American Society of Hematology 140 (1), 16-24, 2022 | 21 | 2022 |
| Donor-derived multiple leukemia antigen–specific T-cell therapy to prevent relapse after transplant in patients with ALL S Naik, S Vasileiou, I Tzannou, M Kuvalekar, A Watanabe, C Robertson, ... Blood, The Journal of the American Society of Hematology 139 (17), 2706-2711, 2022 | 20 | 2022 |
| CD5 CAR T-cells for treatment of patients with relapsed/refractory CD5 expressing T-cell lymphoma demonstrates safety and anti-tumor activity LQ Hill, RH Rouce, TS Smith, L Yang, M Srinivasan, H Zhang, S Perconti, ... Biology of Blood and Marrow Transplantation 26 (3), S237, 2020 | 20 | 2020 |
| Allogeneic, off-the-shelf, SARS-CoV-2-specific T cells (ALVR109) for the treatment of COVID-19 in high-risk patients S Vasileiou, LQ Hill, M Kuvalekar, AG Workineh, A Watanabe, ... Haematologica 108 (7), 1840, 2023 | 18 | 2023 |
| Health disparities experienced by Black and Hispanic Americans with multiple myeloma in the United States: a population-based study S Al Hadidi, D Dongarwar, HM Salihu, RT Kamble, P Lulla, LQC Hill, ... Leukemia & lymphoma 62 (13), 3256-3263, 2021 | 18 | 2021 |
| A phase I trial targeting advanced or metastatic pancreatic cancer using a combination of standard chemotherapy and adoptively transferred nonengineered, multiantigen specific … BG Smaglo, BL Musher, S Vasileiou, M Kuvalekar, A Watanabe, ... Journal of Clinical Oncology 38 (15_suppl), 4622-4622, 2020 | 17 | 2020 |
| Early signals of anti-tumor efficacy and safety with autologous CD5. CAR T-cells in patients with refractory/relapsed T-cell lymphoma RH Rouce, LQC Hill, TS Smith, L Yang, B Boriskie, M Srinivasan, H Zhang, ... Blood 138, 654, 2021 | 12 | 2021 |
| Antitumor efficacy and safety of unedited autologous CD5. CAR T cells in relapsed/refractory mature T-cell lymphomas LQC Hill, RH Rouce, MJ Wu, T Wang, R Ma, H Zhang, B Mehta, ... Blood 143 (13), 1231-1241, 2024 | 11 | 2024 |
| CAR‐T cell therapy for non‐Hodgkin lymphomas: A new treatment paradigm LQ Hill, P Lulla, HE Heslop Advances in cell and gene therapy 2 (3), e54, 2019 | 10 | 2019 |
| Allogeneic haematopoietic cell transplant in patients with relapsed/refractory anaplastic large cell lymphoma F Furqan, KW Ahn, Y Chen, M Kaur, SA Abutalib, N Ahmed, S Ahmed, ... British journal of haematology 200 (1), 54-63, 2023 | 7 | 2023 |
| Enhanced anti-tumor activity of CD5 CAR T cells manufactured with tyrosine kinase inhibitors in patients with relapsed/refractory T-ALL LQC Hill, RH Rouce, TS SMith, B Boriskie, M Srinivasan, SG Thakkar, ... 2023 ASCO Annual Meeting 41 (16_suppl, 7002), 2023 | 5 | 2023 |
| Beyond CD19 CAR-T cells in lymphoma WK Leung, A Ayanambakkam, HE Heslop, LQC Hill Current opinion in immunology 74, 46-52, 2022 | 5 | 2022 |
| Rituximab as adjunctive therapy to BEAM conditioning for autologous stem cell transplantation in Hodgkin lymphoma BD Friend, IN Muhsen, S Patel, LQC Hill, P Lulla, CA Ramos, SR Pingali, ... Bone Marrow Transplantation 57 (4), 579-585, 2022 | 3 | 2022 |
| Commercialization of investigational cell therapy products A Afrough, HE Heslop, LQC Hill Cell Therapy: cGMP Facilities and Manufacturing, 161-178, 2022 | 3 | 2022 |
